

WELCOME TO THE NILE WEBINAR FOR MARCH 2023!

Immunize Nevada is a nonprofit 501c3 coalition that is widely recognized as Nevada's trusted resource for immunization information and community health outreach for all ages. We accomplish this by fostering education and statewide collaboration with a variety of health partners and collaborators.

You may view upcoming web trainings at ImmunizeNevada.org/NILEwebinars

Thank you for joining us today!



HOUSEKEEPING ITEMS

Connectivity Issues	Please log back in and we'll continue where we left off.	
Have a Question?	Locate the Q & A box and type them there. We will address questions throughout the presentation.	
Closed Captions	To enable closed captioning, please click on the "Live Transcript" icon and select "Show Subtitles".	CC
Complete Survey for CEU Credit	In order to receive CEU credit for attending today's webinar, please complete the survey at the end of today's program.	





DISCLAMER

Immunize Nevada's NILE webinars are made possible by the generosity of speakers who donate their time and expertise to benefit the coalition. The expectation and goal is for community partners to gain knowledge on immunization/infectious disease-related topics through a non-branded, unbiased presentation.

The opinions expressed are those of today's presenter and do not necessarily reflect those shared by Immunize Nevada or its pc



Today's Program: Getting the Biggest Bang for Your Buck -Making the Most Out of Your Encounters with Your LGBTQIA+ Patients by Providing Vaccine Preventable Disease Protection





Christina M. Madison, Pharm.D., FCCP, AAHIVP

GETTING THE BIGGEST BANG FOR YOUR BUCK - MAKING THE MOST OUT OF YOUR ENCOUNTERS WITH YOUR LGBTQIA+ PATIENTS BY PROVIDING VACCINE PREVENTABLE DISEASE PROTECTION




NILE Webinar

Immunize Nevada

March 28th, 2023





Christina M. Madison, PharmD, FCCP, AAHIVP

FOUNDER AND CEO - THE PUBLIC HEALTH PHARMACIST, PLLC.

ASSOCIATE PROFESSOR OF PHARMACY PRACTICE - ROSEMAN UNIVERSITY OF HEALTH SCIENCES

LEARNING OUTCOMES

- Discuss how care for persons in the LGBTQIA+ community can be different
- Describe health disparities that disproportionately impact the LGBTQIA+ community
- Analyze the recent Mpox outbreak and why it emphasize the need for routine and regular vaccination services for at risk populations
- Compare and Contrast what vaccines are indicated for STI prevention that can be provided in the outpatient clinic setting
- Review best practices for incorporating vaccination services into daily practices

- • • •
- • • •
- \bullet \bullet \bullet \bullet

BACKGROUND.

- The lesbian, gay, bisexual, transgender or queer (LGBTQ) community is a very diverse patient population
- LGBTQ persons come from all walks of life, and include people of all races and ethnicities, all ages, all socioeconomic statuses, and from all parts of the United States
- There is a need for culturally competent medical care and prevention services that are specific to this population
- Differences in sexual behavior account for some of the disparities, others are associated with social and structural inequities, such as the stigma and discrimination against LGBTQ population
- Discrimination is very common in LGBTQ persons



- LGTBQ+ Statistics
- 39% report rejection by a family member or friend
- 30% threatened or physically attacked
- 21% treated unfairly by an employer
- 30% missed at least one day of school as a youth due to feeling unsafe or uncomfortable
- 61% of transgender persons report physically being attacked
- 55% of transgender persons report job loss due to bias

BACKGROUND

Sexual orientation is how a person characterizes their physical and emotional attraction to others.

Has 3 dimensions:

Identity

Do you consider yourself gay, lesbian, bisexual, straight, queer, something else?

Behavior

What gender(s) do you have sex with?


Attraction

What gender(s) are you attracted to?



- A key principle of effective communication is to use patients' preferred names and pronouns
- Using names and pronouns
 - Transgender persons want others to use pronouns that affirm their gender identity
- Transgender persons often change their name to affirm their gender identity
 - A name that is often different than what is on their insurance or identity documents

STIGMA, DISCRIMINATION, AND HEALTH



LGTBQ+ HEALTH DISPARITIES The perspectives and needs of the LGBTQ community should be considered in public health efforts to improve patient outcomes and eliminate health disparities

The LGBTQ patient population is associated with poorer health status and sexual orientation has been associated with multiple health threats as compared to their heterosexual peers

Understanding these health disparities is imperative to allowing patients to feel comfortable with their providers

Providers need to be educated about these disparities in order to best assist with their healthcare needs

LGTBQ+ HEALTH DISPARITIES

- Anxiety and depression
- HIV and Sexually Transmitted Infections (STIs)
- Homelessness
- Lack of peer or family support
- Smoking
- Substance use
- Suicidal ideations and attempts

LGTBQ+ VACCINATION NEEDS

VACCINATION INDICATIONS

History of sexually transmitted infection

HIV, CT/GC/Syphilis

Homelessness

• Unstable housing, coach surfing, or unhoused

Immunosuppressed

• Due to drug or disease state

Substance Use

- Alcohol dependence (leading to liver disease)
- Current smoker (cannabis, nicotine, vaping)

Sexual orientation and Gender Identity

Men who have sex with men (Same Gender Loving Men) , Transactional Sex



- Routine Recommended Based on Indication
 - Hepatitis A
 - Hepatitis B
 - Human papillomavirus (HPV)
 - Meningococcal (MCV4, MenB)
 - Pneumococcal (PCV15/20, PPSV23)
 - Tdap
 - Zoster (RZV)
- Seasonal/Annual/Outbreaks
 - COVID-19 (mRNA or viral vector)
 - Influenza (IIV4, LAIV4)
 - Mpox
- Persons living with HIV (PLWH) should also be assessed for recommended vaccination based on age as well

VACCINE SCHEDULE

Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger

2022

Vaccines in the Child and Adolescent Immunization Schedule*

Vaccine	Abbreviation(s)	Trade name(s)		
Dengue vaccine	DEN4CYD	Dengvaxia®		
Diphtheria, tetanus, and acellular pertussis vaccine	DTaP	Daptacel [®] Infanrix [®]		
Diphtheria, tetanus vaccine	DT	No trade name		
Haemophilus influenzae type b vaccine	Hib (PRP-T) Hib (PRP-OMP)	ActHIB® Hiberix® PedvaxHIB®		
Hepatitis A vaccine	НерА	Havrix® Vaqta®		
Hepatitis B vaccine	НерВ	Engerix-B [®] Recombivax HB [®]		
Human papillomavirus vaccine	HPV	Gardasil 9®		
Influenza vaccine (inactivated)	IIV4	Multiple		
Influenza vaccine (live, attenuated)	LAIV4	FluMist [®] Quadrivalent		
Measles, mumps, and rubella vaccine	MMR	M-M-R II®		
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-D	Menactra®		
	MenACWY-CRM	Menveo®		
	MenACWY-TT	MenQuadfi®		
Meningococcal serogroup B vaccine	MenB-4C	Bexsero®		
	MenB-FHbp	Trumenba®		
Pneumococcal 13-valent conjugate vaccine	PCV13	Prevnar 13°		
Pneumococcal 23-valent polysaccharide vaccine	PPSV23	Pneumovax 23®		
Poliovirus vaccine (inactivated)	IPV	IPOL [®]		
Rotavirus vaccine	RV1 RV5	Rotarix® RotaTeq®		
Tetanus, diphtheria, and acellular pertussis vaccine	Tdap	Adacel® Boostrix®		
Tetanus and diphtheria vaccine	Td	Tenivac® Tdvax™		
Varicella vaccine	VAR	Varivax [®]		
Combination vaccines (use combination vaccines instead of sep	parate injections when ap	propriate)		
DTaP, hepatitis B, and inactivated poliovirus vaccine	DTaP-HepB-IPV	Pediarix®		
DTaP, inactivated poliovirus, and Haemophilus influenzae type b vaccine	e DTaP-IPV/Hib	Pentacel®		
DTaP and inactivated poliovirus vaccine	DTaP-IPV	Kinrix ^e Quadracel ^e		
DTaP, inactivated poliovirus, <i>Haemophilus influenzae</i> type b, and hepatitis B vaccine	DTaP-IPV-Hib- HepB	Vaxelis®		
Measles, mumps, rubella, and varicella vaccine	MMRV	ProQuad®		

*Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

How to use the child and adolescent immunization schedule

Determine recommended vaccine by age (Table 1)

Determine Assess recommended for add interval for catchup vaccination vaccine (Table 2) medica or othe

Assess need Review vaccine for additional types, frequencies recommended intervals, and vaccines by considerations for medical condition special situations or other indication (Notes) (Table 3)

5 Review

types, frequencies, contraindications intervals, and and precautions considerations for special situations (Appendix)

Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), American Academy of Pediatrics (www.aap.org), American Academy of Family Physicians (www.aap.org), American College of Obstetricians and Gynecologists (www.acog.org), American College of Nurse-Midwives (www.midwife.org), American Academy of Physician Associates (www.aapa.org), and National Association of Pediatric Nurse Practitioners (www.napnap.org).

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or 800-822-7967

Questions or comments

Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays

Download the CDC Vaccine Schedules app for providers at www.cdc.gov/vaccines/schedules/hcp/schedule-app.html

Helpful information

- Complete Advisory Committee on Immunization Practices (ACIP) recommendations: www.cdc.gov/vaccines/hcp/acip-recs/index.html
- General Best Practice Guidelines for Immunization (including contraindications and precautions): www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
- Vaccine information statements:
- www.cdc.gov/vaccines/hcp/vis/index.html
- Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification and outbreak response): www.cdc.gov/vaccines/pubs/surv-manual
- ACIP Shared Clinical Decision-Making Recommendations www.cdc.gov/vaccines/acip/acip-scdm-faqs.html



U.S. Department of Health and Human Services Centers for Disease Control and Prevention Scan QR code for access to online schedule



PS://WWW.CDC.GOV/VACCINES/SCHEDULES/HCP/SCHEDULE-RELATED-RESOURCES.HTML

Table 1 Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2022

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2).

to determine minimum intervals betw	cent doses,	see the co	terr up ser	caare (rac	//C 2/.									_			
Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos	18 mos	19–23 mos	2–3 yrs	4–6 yrs	7–10 yrs	11–12 yrs	13–15 yrs	16 yrs	17–18 yrs
Hepatitis B (HepB)	1 st dose	< 2 nd	dose>				3 rd dose		>								
Rotavirus (RV): RV1 (2-dose series), RV5 (3-dose series)			1st dose	2 nd dose	See Notes												
Diphtheria, tetanus, acellular pertussis (DTaP <7 yrs)			1 st dose	2 nd dose	3 rd dose			∢ 4 th c	lose>			5 th dose					
Haemophilus influenzae type b (Hib)			1 st dose	2 nd dose	See Notes		3 rd or 4 See I	th dose, Notes									
Pneumococcal conjugate (PCV13)			1 st dose	2 nd dose	3 rd dose		∢ 4 th c	lose>									
Inactivated poliovirus (IPV <18 yrs)			1ª dose	2 nd dose	•		3 rd dose		•			4 th dose					
Influenza (IIV4)							P	innual vacci	ination 1 or	2 doses			-or -	Annua	vaccination	1 dose on	ly
Influenza (LAIV4)												l vaccinatio r 2 doses		Annua	vaccination	1 dose on	ly
Measles, mumps, rubella (MMR)					Seef	Notes	∢ 1 st c	lose>				2 nd dose					
Varicella (VAR)							∢ 1 st c	lose>				2 nd dose					
Hepatitis A (HepA)					Seel	Notes	3	2-dose serie	es, See Note	25							
Tetanus, diphtheria, acellular pertussis (Tdap ≥7 yrs)														1 dose			
Human papillomavirus (HPV)													85	See Notes			
Meningococcal (MenACWY-D≥9 mos, MenACWY-CRM≥2 mos, MenACWY-TT ≥2years)								See Notes						1 st dose		2 nd dose	
Meningococcal B (MenB-4C, MenB- FHbp)															See No	tes	
Pneumococcal polysaccharide (PPSV23)					See Notes												
Dengue (DEN4CYD; 9-16 yrs)						Seropositive in endemic areas only (See Notes)											
Range of recommended ages for all children		recommend up vaccinati			nge of recor certain higł				mended va jin in this a				ed vaccination			recomme tapplicabl	

SCHEDULE BY AGE

https://www.cdc.gov /vaccines/schedules/ hcp/schedulerelatedresources.html



Table 2 Recommended Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who Are More than 1 Month Behind, United States, 2022

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child's age. Always use this table in conjunction with Table 1 and the Notes that follow.

			Children age 4 months through 6 years		
Vaccine	Minimum Age for		Minimum Interval Between Doses		
	Dose 1	Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dose
Hepatitis B	Birth	4 weeks	8 weeks and at least 16 weeks after first dose minimum age for the final dose is 24 weeks		
Rotavirus	6 weeks Maximum age for first dose is 14 weeks, 6 days.	4 weeks	4 weeks maximum age for final dose is 8 months, 0 days		
Diphtheria, tetanus, and acellular pertussis	6 weeks	4 weeks	4 weeks	6 months	6 months
Haemophilus influenzae type b	6 weeks	No further doses needed if first dose was administered at age 15 months or older. 4 weeks iffirst dose was administered before the 1 st birthday. 8 weeks (as final dose) if first dose was administered at age 12 through 14 months.	No further doses needed if previous dose was administered at age 15 months or older 4 weeks if current age is younger than 12 months and first dose was administered at younger than age 7 months and at least 1 previous dose was PRP-1 (ActHib [*] , Pentacel [*] , Hiberix [*]), Vaxelis [*] or unknown 8 weeks and age 12 through 59 months (as final dose) if current age is younger than 12 months and first dose was administered at age 7 through 11 months; OR if current age is 12 through 59 months and first dose was administered before the 1 st birthday and second dose was administered at younger than 15 months; OR if both doses were PedvaxHIB [*] and were administered before the 1st birthday	8 weeks (as final dose) This dose only necessary for children age 12 through 59 months who received 3 doses before the 1 st birthday.	
Pneumococcal conjugate	6 weeks	No further doses needed for healthy children if first dose was administered at age 24 months or older 4 weeks if first dose was administered before the 1 st birthday 8 weeks (as final dose for healthy children) if first dose was administered at the 1 st birthday or after	No further doses needed for healthy children if previous dose was administered at age 24 months or older 4 weeks if current age is younger than 12 months and previous dose was administered at <7 months old 8 weeks (as final dose for healthy children) if previous dose was administered between 7–11 months (wait until at least 12 months old); OR if current age is 12 months or older and at least 1 dose was administered before age 12 months	8 weeks (as final dose) This dose only necessary for children age 12 through 59 months who received 3 doses before age 12 months or for children at high risk who received 3 doses at any age.	
Inactivated poliovirus	6 weeks	4 weeks	4 weeks if current age is <4 years 6 months (as final dose) if current age is 4 years or older	6 months (minimum age 4 years for final dose)	
Measles, mumps, rubella	12 months	4 weeks			
Varicella	12 months	3 months			
Hepatitis A	12 months	6 months			
Meningococcal ACWY		8 weeks	See Notes	See Notes	
			Children and adolescents age 7 through 18 years		
Meningococcal ACWY	Not applicable (N/A)	8 weeks			
Tetanus, diphtheria; tetanus, diphtheria, and acellular pertussis	7 years	4 weeks	4 weeks if first dose of DTaP/DT was administered before the 1 st birthday 6 months (as final dose) if first dose of DTaP/DT or Tdap/Td was administered at or after the 1 st birthday	6 months if first dose of DTaP/DT was administered before the 1 st birthday	
Human papillomavirus	9 years	Routine dosing intervals are recommended.			
Hepatitis A	N/A	6 months			
Hepatitis B	N/A	4 weeks	8 weeks and at least 16 weeks after first dose		
Inactivated poliovirus	N/A	4 weeks	6 months A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose.	A fourth dose of IPV is indicated if all previous doses were administered at <4 years or if the third dose was administered <6 months after the second dose.	
Measles, mumps, rubella	N/A	4 weeks			
Varicella	N/A	3 months if younger than age 13 years. 4 weeks if age 13 years or older			

CATCH-UP SCHEDULE

https://www.cdc.gov/vaccine s/schedules/hcp/schedulerelated-resources.html

Table 3

Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2022


Always use this table in conjunction with Table 1 and the Notes that follow.

Always use this table in to										
			HIV infection	n CD4+ count ¹						
VACCINE	Pregnancy	Immunocom- promised status (excluding HIV infection)	<15% or total CD4 cell count of <200/mm ³	≥15% and total CD4 cell count of ≥200/mm ³	Kidney failure, end-stage renal disease, or on hemodialysis	Heart disease or chronic lung disease	CSF leak or cochlear implant	Asplenia or persistent complement component deficiencies	Chronic liver disease	Diabetes
Hepatitis B										
Rotavirus		SCID ²								
Diphtheria, tetanus, and acellular pertussis (DTaP)										
Haemophilus influenzae type b										
Pneumococcal conjugate										
Inactivated poliovirus										
Influenza (IIV4)										
Influenza (LAIV4)						Asthma, wheezing: 2–4yrs ³				
Measles, mumps, rubella	*									
Varicella	*									
Hepatitis A										
Tetanus, diphtheria, and acellular pertussis (Tdap)										
Human papillomavirus	*									
Meningococcal ACWY				19191919191						
Meningococcal B										
Pneumococcal polysaccharide										
Dengue										
Vaccination according t routine schedule recommended	o the	Recommended for persons with an addition factor for which the vace would be indicated	onalrisk <mark></mark> a ccine n	accination is recomr nd additional doses ecessary based on n ondition or vaccine.	may be nedical	Precaution—vaccine night be indicated if benefit of protection outweighs risk of adverse reaction	not be adm	ated or not ded—vaccine should inistered after pregnancy	No recomme applicable	ndation/not

1 For additional information regarding HIV laboratory parameters and use of live vaccines, see the General Best Practice Guidelines for Immunization, "Altered Immunocompetence," at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html and Table 4-1 (footnote J) at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html. 2 Severe Combined Immunodeficiency

https://www.cdc.gov/vaccines/schedules/hcp/schedule-related-resources.html

3 LAIV4 contraindicated for children 2-4 years of age with asthma or wheezing during the preceding 12 months



SCHEDULE FOOTNOTES

Notes

Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2022

For vaccination recommendations for persons ages 19 years or older, see the Recommended Adult Immunization Schedule, 2022.

Additional information

COVID-19 Vaccination

COVID-19 vaccines are recommended for use within the scope of the Emergency Use Authorization or Biologics License Application for the particular vaccine. ACIP recommendations for the use of COVID-19 vaccines can be found at www.cdc.gov/ vaccines/hcp/acip-recs/vacc-specific/covid-19.html.

CDC's interim clinical considerations for use of COVID-19 vaccines can be found at www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html.

- Consult relevant ACIP statements for detailed recommendations at www.cdc.gov/vaccines/hcp/acip-recs/index.html.
- For calculating intervals between doses, 4 weeks = 28 days. Intervals of ≥4 months are determined by calendar months.
- Within a number range (e.g., 12–18), a dash (–) should be read as "through."
- Vaccine doses administered ≤4 days before the minimum age or interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum age or minimum interval should not be counted as valid and should be repeated as age appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see Table 3-1, Recommended and minimum ages and intervals between vaccine doses, in *General Best Practice Guidelines for Immunization* at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html.
- Information on travel vaccination requirements and recommendations is available at www.cdc.gov/travel/.
- For vaccination of persons with immunodeficiencies, see Table 8-1, Vaccination of persons with primary and secondary immunodeficiencies, in *General Best Practice Guidelines for Immunization* at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/ immunocompetence.html, and Immunization in Special Clinical Circumstances (In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2018 Report of the Committee on Infectious Diseases.* 31st ed. Itasca, IL: American Academy of Pediatrics; 2018:67–111).
- For information about vaccination in the setting of a vaccinepreventable disease outbreak, contact your state or local health department.
- The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. All routine child and adolescent vaccines are covered by VICP except for pneumococcal polysaccharide vaccine (PPSV23). For more information, see www.hrsa.gov/vaccinecompensation/index.html.

Dengue vaccination (minimum age: 9 years)

Routine vaccination

- Age 9–16 years living in dengue endemic areas AND have laboratory confirmation of previous dengue infection
- 3-dose series administered at 0, 6, and 12 months
- Endemic areas include Puerto Rico, American Samoa, US Virgin Islands, Federated States of Micronesia, Republic of Marshall Islands, and the Republic of Palau. For updated guidance on dengue endemic areas and pre-vaccination laboratory testing see <u>www.cdc.gov/mmwr/</u> volumes/70/rr/rr7006a1.htm?s_cid=rr7006a1_w and <u>www.cdc.gov/</u> dengue/vaccine/hcp/index.html

Diphtheria, tetanus, and pertussis (DTaP) vaccination (minimum age: 6 weeks [4 years for Kinrix[®] or Quadracel[®]])

Routine vaccination

- 5-dose series at age 2, 4, 6, 15–18 months, 4–6 years
- **Prospectively:** Dose 4 may be administered as early as age 12 months if at least 6 months have elapsed since dose 3.
- Retrospectively: A 4th dose that was inadvertently administered as early as age 12 months may be counted if at least 4 months have elapsed since dose 3.

Catch-up vaccination

- Dose 5 is not necessary if dose 4 was administered at age 4 years or older and at least 6 months after dose 3.
- For other catch-up guidance, see Table 2.

Special situations

 Wound management in children less than age 7 years with history of 3 or more doses of tetanus-toxoid-containing vaccine: For all wounds except clean and minor wounds, administer DTaP if more than 5 years since last dose of tetanus-toxoid-containing vaccine. For detailed information, see www.cdc.gov/mmwr/volumes/67/rr/rt6702a1.htm.

Haemophilus influenzae type b vaccination (minimum age: 6 weeks)

Routine vaccination

- ActHIB[®], Hiberix[®], Pentacel[®], or Vaxelis[®]: 4-dose series (3 dose primary series at age 2, 4, and 6 months, followed by a booster dose* at age 12–15 months)
- *Vaxelis[®] is not recommended for use as a booster dose. A different Hib-containing vaccine should be used for the booster dose.
- PedvaxHIB®: 3-dose series (2-dose primary series at age 2 and 4 months, followed by a booster dose at age 12–15 months)

Catch-up vaccination

- Dose 1 at age 7–11 months: Administer dose 2 at least 4 weeks later and dose 3 (final dose) at age 12–15 months or 8 weeks after dose 2 (whichever is later).
- Dose 1 at age 12–14 months: Administer dose 2 (final dose) at least 8 weeks after dose 1.

- Dose 1 before age 12 months and dose 2 before age 15 months: Administer dose 3 (final dose) at least 8 weeks after dose 2.
- 2 doses of PedvaxHIB[®] before age 12 months: Administer dose 3 (final dose) at 12–59 months and at least 8 weeks after dose 2.
- 1 dose administered at age 15 months or older: No further doses needed
- Unvaccinated at age 15–59 months: Administer 1 dose.
- Previously unvaccinated children age 60 months or older who are not considered high risk: Do not require catch-up vaccination

For other catch-up guidance, see Table 2. Vaxelis[®] can be used for catch-up vaccination in children less than age 5 years. Follow the catch-up schedule even if Vaxelis[®] is used for one or more doses. For detailed information on use of Vaxelis[®] see www.cdc.gov/mmwr/volumes/69/wr/mm6905a5.htm.

Special situations

- Chemotherapy or radiation treatment: Age 12–59 months
- Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose

Doses administered within 14 days of starting therapy or during therapy should be repeated at least 3 months after therapy completion.

• Hematopoietic stem cell transplant (HSCT):

- 3-dose series 4 weeks apart starting 6 to 12 months after successful transplant, regardless of Hib vaccination history
- Anatomic or functional asplenia (including sickle cell disease): Age 12–59 months
- Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose
- Unvaccinated* persons age 5 years or older
- 1 dose

• Elective splenectomy:

- Unvaccinated* persons age 15 months or older
- 1 dose (preferably at least 14 days before procedure)

HIV infection:

Age 12-59 months

- Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose

Unvaccinated* persons age 5–18 years

- 1 dose
- Immunoglobulin deficiency, early component complement deficiency:

Age 12-59 months

- Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose
- *Unvaccinated = Less than routine series (through age 14 months) OR no doses (age 15 months or older)

Notes

Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2022

Hepatitis A vaccination

(minimum age: 12 months for routine vaccination)

Routine vaccination

• 2-dose series (minimum interval: 6 months) at age 12–23 months

Catch-up vaccination

- Unvaccinated persons through age 18 years should complete a 2-dose series (minimum interval: 6 months).
- Persons who previously received 1 dose at age 12 months or older should receive dose 2 at least 6 months after dose 1.
- Adolescents age 18 years or older may receive the combined HepA and HepB vaccine, Twinrix[®], as a 3-dose series (0, 1, and 6 months) or 4-dose series (3 doses at 0, 7, and 21–30 days, followed by a booster dose at 12 months).

International travel

- Persons traveling to or working in countries with high or intermediate endemic hepatitis A (www.cdc.gov/travel/):
- Infants age 6-11 months: 1 dose before departure; revaccinate with 2 doses, separated by at least 6 months, between age 12-23 months.
- Unvaccinated age 12 months or older: Administer dose 1 as soon as travel is considered.

Hepatitis B vaccination (minimum age: birth)

Birth dose (monovalent HepB vaccine only)

Mother is HBsAg-negative:

- All medically stable infants \geq 2,000 grams: 1 dose within 24 hours of birth
- Infants <2,000 grams: Administer 1 dose at chronological age 1 month or hospital discharge (whichever is earlier and even if weight is still <2,000 grams).

Mother is HBsAg-positive:

- Administer HepB vaccine and hepatitis B immune globulin (HBIG) (in separate limbs) within 12 hours of birth, regardless of birth weight. For infants <2,000 grams, administer 3 additional doses of vaccine (total of 4 doses) beginning at age 1 month.
- Test for HBsAg and anti-HBs at age 9–12 months. If HepB series is delayed, test 1–2 months after final dose.

• Mother's HBsAg status is unknown:

- Administer **HepB vaccine** within 12 hours of birth, regardless of birth weight.
- For infants <2,000 grams, administer HBIG in addition to HepB vaccine (in separate limbs) within 12 hours of birth. Administer 3 additional doses of vaccine (total of 4 doses) beginning at age 1 month.
- Determine mother's HBsAg status as soon as possible. If mother is HBsAg-positive, administer HBIG to infants ≥2,000 grams as soon as possible, but no later than 7 days of age.

Routine series

- 3-dose series at age 0, 1–2, 6–18 months (use monovalent HepB vaccine for doses administered before age 6 weeks)
- Infants who did not receive a birth dose should begin the series as soon as feasible (see Table 2).

- Administration of 4 doses is permitted when a combination vaccine containing HepB is used after the birth dose.
- Minimum age for the final (3rd or 4th) dose: 24 weeks
- Minimum intervals: dose 1 to dose 2: 4 weeks / dose 2 to dose 3: 8 weeks / dose 1 to dose 3: 16 weeks (when 4 doses are administered, substitute "dose 4" for "dose 3" in these calculations)

Catch-up vaccination

- Unvaccinated persons should complete a 3-dose series at 0, 1–2, 6 months.
- Adolescents age 11–15 years may use an alternative 2-dose schedule with at least 4 months between doses (adult formulation Recombivax HB[®] only).
- Adolescents age 18 years or older may receive a 2-dose series of HepB (Heplisav-B[®]) at least 4 weeks apart.
- Adolescents age 18 years or older may receive the combined HepA and HepB vaccine, Twinrix®, as a 3-dose series (0, 1, and 6 months) or 4-dose series (3 doses at 0, 7, and 21–30 days, followed by a booster dose at 12 months).
- For other catch-up guidance, see Table 2.

Special situations

- Revaccination is not generally recommended for persons with a normal immune status who were vaccinated as infants, children, adolescents, or adults.
- Post-vaccination serology testing and revaccination (if anti-HBs < 10mlU/mL) is recommended for certain populations, including:
- Infants born to HBsAg-positive mothers
- Hemodialysis patients
- Other immunocompromised persons

For detailed revaccination recommendations, see www.cdc.gov/ vaccines/hcp/acip-recs/vacc-specific/hepb.html.

Human papillomavirus vaccination (minimum age: 9 years)

Routine and catch-up vaccination

- HPV vaccination routinely recommended at age 11–12 years (can start at age 9 years) and catch-up HPV vaccination recommended for all persons through age 18 years if not adequately vaccinated
- 2- or 3-dose series depending on age at initial vaccination:
- Age 9–14 years at initial vaccination: 2-dose series at 0, 6–12 months (minimum interval: 5 months; repeat dose if administered too soon)
- Age 15 years or older at initial vaccination: 3-dose series at 0, 1–2 months, 6 months (minimum intervals: dose 1 to dose 2: 4 weeks / dose 2 to dose 3: 12 weeks / dose 1 to dose 3: 5 months; repeat dose if administered too soon)
- Interrupted schedules: If vaccination schedule is interrupted, the series does not need to be restarted.
- No additional dose recommended when any HPV vaccine series has been completed using the recommended dosing intervals.

Special situations

- Immunocompromising conditions, including HIV infection: 3-dose series, even for those who initiate vaccination at age 9 through 14 years.
- History of sexual abuse or assault: Start at age 9 years.

 Pregnancy: Pregnancy testing not needed before vaccination; HPV vaccination not recommended until after pregnancy; no intervention needed if vaccinated while pregnant

Influenza vaccination

(minimum age: 6 months [IIV], 2 years [LAIV4], 18 years [recombinant influenza vaccine, RIV4])

Routine vaccination

- Use any influenza vaccine appropriate for age and health status annually:
- 2 doses, separated by at least 4 weeks, for children age 6 months-8 years who have received fewer than 2 influenza vaccine doses before July 1, 2021, or whose influenza vaccination history is unknown (administer dose 2 even if the child turns 9 between receipt of dose 1 and dose 2)
- 1 dose for **children age 6 months–8 years** who have received at least 2 influenza vaccine doses before July 1, 2021
- 1 dose for all persons age 9 years or older
- For the 2021-2022 season, see www.cdc.gov/mmwr/volumes/70/rr/ rr7005a1.htm.
- For the 2022–23 season, see the 2022–23 ACIP influenza vaccine recommendations.

Special situations

- Egg allergy, hives only: Any influenza vaccine appropriate for age and health status annually
- Egg allergy with symptoms other than hives (e.g., angioedema, respiratory distress) or required epinephrine or another emergency medical intervention: see Appendix listing contraindications and precautions
- Severe allergic reaction (e.g., anaphylaxis) to a vaccine component or a previous dose of any influenza vaccine: see Appendix listing contraindications and precautions

Measles, mumps, and rubella vaccination (minimum age: 12 months for routine vaccination)

Routine vaccination

- 2-dose series at age 12–15 months, age 4–6 years
- MMR or MMRV may be administered

Note: For dose 1 in children age 12–47 months, it is recommended to administer MMR and varicella vaccines separately. MMRV may be used if parents or caregivers express a preference.

Catch-up vaccination

- Unvaccinated children and adolescents: 2-dose series at least 4 weeks apart
- The maximum age for use of MMRV is 12 years.
- Minimum interval between MMRV doses: 3 months

Special situations

International travel

- Infants age 6–11 months: 1 dose before departure; revaccinate with 2-dose series at age 12–15 months (12 months for children in high-risk areas) and dose 2 as early as 4 weeks later.
- Unvaccinated children age 12 months or older: 2-dose series at least 4 weeks apart before departure

https://www.cdc/gov/vaccines/schedules/hcp/schedule-related-resources.html

Notes

Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2022

Meningococcal serogroup A,C,W,Y vaccination

(minimum age: 2 months [MenACWY-CRM, Menveo], 9 months [MenACWY-D, Menactra], 2 years [MenACWY-TT, MenQuadfi])

Routine vaccination

2-dose series at age 11–12 years; 16 years

Catch-up vaccination

- Age 13–15 years: 1 dose now and booster at age 16–18 years (minimum interval: 8 weeks)
- Age 16–18 years: 1 dose

Special situations

Anatomic or functional asplenia (including sickle cell disease), HIV infection, persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use:

- Menveo
- Dose 1 at age 2 months: 4-dose series (additional 3 doses at age 4, 6 and 12 months)
- Dose 1 at age 3-6 months: 3- or 4- dose series (dose 2 [and dose 3 if applicable] at least 8 weeks after previous dose until a dose is received at age 7 months or older, followed by an additional dose at least 12 weeks later and after age 12 months)
- Dose 1 at age 7–23 months: 2-dose series (dose 2 at least 12 weeks after dose 1 and after age 12 months)
- Dose 1 at age 24 months or older: 2-dose series at least 8 weeks apart Menactra
- Persistent complement component deficiency or complement inhibitor use:
- · Age 9–23 months: 2-dose series at least 12 weeks apart
- · Age 24 months or older: 2-dose series at least 8 weeks apart Anatomic or functional asplenia, sickle cell disease, or HIV infection:
- Age 9–23 months: Not recommended
- · Age 24 months or older: 2-dose series at least 8 weeks apart
- Menactra® must be administered at least 4 weeks after completion of PCV13 series.

MenQuadfi[®]

 Dose 1 at age 24 months or older: 2-dose series at least 8 weeks apart Travel in countries with hyperendemic or epidemic meningococcal disease, including countries in the African meningitis belt or during the Hajj (www.cdc.gov/travel/):

Children less than age 24 months:

- Menveo[®] (age 2–23 months)

· Dose 1 at age 2 months: 4-dose series (additional 3 doses at age 4, 6 and 12 months)

Dose 1 at age 3-6 months: 3- or 4- dose series (dose 2 [and dose 3 if applicable] at least 8 weeks after previous dose until a dose is received at age 7 months or older, followed by an additional dose at least 12 weeks later and after age 12 months)

Dose 1 at age 7–23 months: 2-dose series (dose 2 at least 12 weeks after dose 1 and after age 12 months)

- Menactra® (age 9–23 months)
- 2-dose series (dose 2 at least 12 weeks after dose 1; dose 2 may be administered as early as 8 weeks after dose 1 in travelers)
- Children age 2 years or older: 1 dose Menveo®, Menactra®, or MenOuadfi[®]

First-year college students who live in residential housing (if not

previously vaccinated at age 16 years or older) or military recruits:

I dose Menveo[®], Menactra[®], or MenQuadfi[®]

Adolescent vaccination of children who received MenACWY prior to age 10 years:

- Children for whom boosters are recommended because of an ongoing increased risk of meningococcal disease (e.g., those with complement deficiency, HIV, or asplenia): Follow the booster schedule for persons at increased risk.
- Children for whom boosters are not recommended (e.g., a healthy child who received a single dose for travel to a country where meningococcal disease is endemic): Administer MenÁCWY according to the recommended adolescent schedule with dose 1 at age 11-12 years and dose 2 at age 16 years.

Note: Menactra[®] should be administered either before or at the same time as DTaP. MenACWY vaccines may be administered simultaneously with MenB vaccines if indicated, but at a different anatomic site, if feasible.

For MenACWY booster dose recommendations for groups listed under "Special situations" and in an outbreak setting and additional meningococcal vaccination information, see www.cdc.gov/mmwr/ volumes/69/rr/rr6909a1.htm.

Meningococcal serogroup B vaccination (minimum age: 10 years [MenB-4C, Bexsero®; MenB-FHbp, Trumenba[®]])

Shared clinical decision-making

- Adolescents not at increased risk age 16–23 years (preferred age 16-18 years) based on shared clinical decision-making:
- Bexsero®: 2-dose series at least 1 month apart
- Trumenba[®]: 2-dose series at least 6 months apart; if dose 2 is administered earlier than 6 months, administer a 3rd dose at least 4 months after dose 2.

Special situations

Anatomic or functional asplenia (including sickle cell disease), persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use:

- Bexsero®: 2-dose series at least 1 month apart
- Trumenba®: 3-dose series at 0, 1-2, 6 months

Note: Bexsero® and Trumenba® are not interchangeable; the same product should be used for all doses in a series.

For MenB booster dose recommendations for groups listed under "Special situations" and in an outbreak setting and additional meningococcal vaccination information, see www.cdc.gov/mmwr/ volumes/69/rr/rr6909a1.htm.

Pneumococcal vaccination (minimum age: 6 weeks [PCV13], 2 years [PPSV23])

Routine vaccination with PCV13

4-dose series at age 2, 4, 6, 12–15 months

Catch-up vaccination with PCV13

- 1 dose for healthy children age 24–59 months with any incomplete* PCV13 series
- For other catch-up guidance, see Table 2.

Special situations

Underlying conditions below: When both PCV13 and PPSV23 are indicated, administer PCV13 first. PCV13 and PPSV23 should not be administered during same visit.

Chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma treated with high-dose, oral corticosteroids); diabetes mellitus:

Age 2–5 years

- Any incomplete* series with:
- 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13 dose)
- Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose and administered 8 weeks apart)
- No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after completing) all recommended PCV13 doses)

Age 6–18 years

 No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after completing all recommended PCV13 doses)

Cerebrospinal fluid leak, cochlear implant:

- Age 2–5 years
 - Any incomplete* series with: - 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13
 - dose)
 - Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose and administered 8 weeks apart)
 - No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose)

Age 6–18 years

- No history of either PCV13 or PPSV23: 1 dose PCV13, 1 dose PPSV23 at least 8 weeks later
- Any PCV13 but no PPSV23: 1 dose PPSV23 at least 8 weeks after the most recent dose of PCV13
- PPSV23 but no PCV13: 1 dose PCV13 at least 8 weeks after the most recent dose of PPSV23

Sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiency; HIV infection; chronic renal failure; nephrotic syndrome; malignant neoplasms, leukemias, lymphomas, Hodgkin disease, and other diseases associated with treatment with immunosuppressive drugs or radiation therapy; solid organ transplantation; multiple myeloma:

Age 2-5 years

- Any incomplete* series with:
- 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13 dose)
- Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose and administered 8 weeks apart)
- No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose) and a dose 2 of PPSV23 5 years later

Age 6–18 years

- No history of either PCV13 or PPSV23: 1 dose PCV13, 2 doses PPSV23 (dose 1 of PPSV23 administered 8 weeks after PCV13 and dose 2 of PPSV23 administered at least 5 years after dose 1 of PPSV23)
- Any PCV13 but no PPSV23: 2 doses PPSV23 (dose 1 of PPSV23) administered 8 weeks after the most recent dose of PCV13 and dose 2 of PPSV23 administered at least 5 years after dose 1 of PPSV23)
- PPSV23 but no PCV13: 1 dose PCV13 at least 8 weeks after the most recent PPSV23 dose and a dose 2 of PPSV23 administered 5 years after dose 1 of PPSV23 and at least 8 weeks after a dose of PCV13

c/gov/vaccines/schedules/hcp/schedule-related-resources.html



Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2022

Chronic liver disease, alcoholism:

Age 6–18 years

 No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose)

*Incomplete series = Not having received all doses in either the recommended series or an age-appropriate catch-up series See Tables 8, 9, and 11 in the ACIP pneumococcal vaccine recommendations (www.cdc.gov/mmwr/pdf/rr/rr5911.pdf) for complete schedule details.

Poliovirus vaccination (minimum age: 6 weeks)

Routine vaccination

- 4-dose series at ages 2, 4, 6–18 months, 4–6 years; administer the final dose on or after age 4 years and at least 6 months after the previous dose.
- 4 or more doses of IPV can be administered before age 4 years when a combination vaccine containing IPV is used. However, a dose is still recommended on or after age 4 years and at least 6 months after the previous dose.

Catch-up vaccination

- In the first 6 months of life, use minimum ages and intervals only for travel to a polio-endemic region or during an outbreak.
- IPV is not routinely recommended for U.S. residents age 18 years or older.

Series containing oral polio vaccine (OPV), either mixed OPV-IPV or OPV-only series:

- Total number of doses needed to complete the series is the same as that recommended for the U.S. IPV schedule. See www.cdc.gov/ mmwr/volumes/66/wr/nm6601a6.htm?s %20cid=mm6601a6 w.
- Only trivalent OPV (tOPV) counts toward the U.S. vaccination requirements.
- Doses of OPV administered before April 1, 2016, should be counted (unless specifically noted as administered during a campaign).
- Doses of OPV administered on or after April 1, 2016, should not be counted.
- For guidance to assess doses documented as "OPV," see www.cdc.gov/mmwr/volumes/66/wr/mm6606a7.htm?s_ cid=mm6606a7_w.
- For other catch-up guidance, see Table 2.

Rotavirus vaccination (minimum age: 6 weeks)

Routine vaccination

- Rotarix®: 2-dose series at age 2 and 4 months
- RotaTeg®: 3-dose series at age 2, 4, and 6 months
- If any dose in the series is either **RotaTeq**[®] or unknown, default to 3-dose series.

Catch-up vaccination

- Do not start the series on or after age 15 weeks, 0 days.
- The maximum age for the final dose is 8 months, 0 days.
- For other catch-up guidance, see Table 2.

Tetanus, diphtheria, and pertussis (Tdap) vaccination

(minimum age: 11 years for routine vaccination, 7 years for catch-up vaccination)

Routine vaccination

- Adolescents age 11-12 years: 1 dose Tdap
- **Pregnancy:** 1 dose Tdap during each pregnancy, preferably in early part of gestational weeks 27–36.
- Tdap may be administered regardless of the interval since the last tetanus- and diphtheria-toxoid-containing vaccine.

Catch-up vaccination

- Adolescents age 13–18 years who have not received Tdap: 1 dose Tdap, then Td or Tdap booster every 10 years
- Persons age 7–18 years not fully vaccinated with DTaP: 1 dose Tdap as part of the catch-up series (preferably the first dose); if additional doses are needed, use Td or Tdap.
- Tdap administered at age 7–10 years:
- **Children age 7–9 years** who receive Tdap should receive the routine Tdap dose at age 11–12 years.
- Children age 10 years who receive Tdap do not need the routine Tdap dose at age 11–12 years.
- DTaP inadvertently administered on or after age 7 years:
- Children age 7–9 years: DTaP may count as part of catch-up series. Administer routine Tdap dose at age 11–12 years.
 Children age 10–18 years: Count dose of DTaP as the adolescent
- Tdap booster.
- For other catch-up guidance, see Table 2.

Special situations

- Wound management in persons age 7 years or older with history of 3 or more doses of tetanus-toxoid-containing vaccine: For clean and minor wounds, administer Tdap or Td if more than 10 years since last dose of tetanus-toxoid-containing vaccine; for all other wounds, administer Tdap or Td if more than 5 years since last dose of tetanus-toxoid-containing vaccine. Tdap is preferred for persons age 11 years or older who have not previously received Tdap or whose Tdap history is unknown. If a tetanus-toxoid-containing vaccine is indicated for a preqnant adolescent, use Tdap.
- For detailed information, see www.cdc.gov/mmwr/volumes/69/wr/ mm6903a5.htm.

*Fully vaccinated = 5 valid doses of DTaP OR 4 valid doses of DTaP if dose 4 was administered at age 4 years or older

Varicella vaccination (minimum age: 12 months)

Routine vaccination

- 2-dose series at age 12–15 months, 4–6 years
- VAR or MMRV may be administered*
- Dose 2 may be administered as early as 3 months after dose 1 (a dose inadvertently administered after at least 4weeks may be counted as valid)

***Note**: For dose 1 in children age 12–47 months, it is recommended to administer MMR and varicella vaccines separately. MMRV may be used if parents or caregivers express a preference.

Catch-up vaccination

- Ensure persons age 7–18 years without evidence of immunity (see MMWR at www.cdc.gov/mmwr/pdf/rr/rr5604.pdf) have a 2-dose series:
- Age 7–12 years: routine interval: 3 months (a dose inadvertently administered after at least 4 weeks may be counted as valid)
- Age 13 years and older: routine interval: 4–8 weeks (minimum interval: 4 weeks)
- The maximum age for use of MMRV is 12 years.

2/17/2022

Centers for Disease Control and Prevention | Recommended Child and Adolescent Immunization Schedule, United States, 2022

Appendix

Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2022

Guide to Contraindications and Precautions to Commonly Used Vaccines

Adapted from Table 4-1 in Advisory Committee on Immunization Practices (ACIP) General Best Practice Guidelines for Immunization: Contraindication and Precautions available at www.cdc.gov/vaccines/hcp/aciprecs/general-recs/contraindications.html and ACIP's Recommendations for the Prevention and Control of 2021-22 seasonal influenza with Vaccines available at www.cdc.gov/mmwr/volumes/70/rr/rr7005a1.htm.

Interim clinical considerations for use of COVID-19 vaccines including contraindications and precautions can be found at

www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html

Vaccine	Contraindications ¹	Precautions ²
Influenza, egg-based, inactivated injectable (IIV4)	 Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency) Severe allergic reaction (e.g., anaphylaxis) to any vaccine component³ (excluding egg) 	 Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Persons with egg allergy with symptoms other than hives (e.g., angioedema, respiratory distress) or required epinephrine or another emergency medical intervention: Any influenza vaccine appropriate for age and health status may be administered. If using egg-based IIV4, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist. Moderate or severe acute illness with or without fever
Influenza, cell culture-based inactivated injectable [(ccllV4), Flucelvax [®] Quadrivalent]	• Severe allergic reaction (e.g., anaphylaxis) to any ccIIV of any valency, or to any component ³ of ccIIV4	 Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg-based IIV, RIV, or LAIV of any valency. If using ccIV4, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist. Moderate or severe acute illness with or without fever
Influenza, recombinant injectable [(RIV4), Flublok® Quadrivalent]	• Severe allergic reaction (e.g., anaphylaxis) to any RIV of any valency, or to any component ³ of RIV4	 Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg- based IIV, ccIIV, or LAIV of any valency. If using RIV4, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist. Moderate or severe acute illness with or without fever
Influenza, live attenuated [LAIV4, Flumist® Quadrivalent]	 Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency) Severe allergic reaction (e.g., anaphylaxis) to any vaccine component³ (excluding egg) Children age 2 – 4 years with a history of asthma or wheezing Anatomic or functional asplenia Immunocompromised due to any cause including, but not limited to, medications and HIV infection Close contacts or caregivers of severely immunosuppressed persons who require a protected environment Pregnancy Cochlear implant Active communication between the cerebrospinal fluid (CSF) and the oropharynx, nasopharynx, nose, ear or any other cranial CSF leak Children and adolescents receiving aspirin or salicylate-containing medications Received influenza antiviral medications soltamivir or zanamivir within the previous 48 hours, peramivir within the previous 5 days, or baloxavir within the previous 17 days 	 Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Asthma in persons aged 5 years old or older Persons with egg allergy with symptoms other than hives (e.g., angioedema, respiratory distress) or required epinephrine or another emergency medical intervention: Any influenza vaccine appropriate for age and health status may be administered. If using LAIV4 (which is egg based), administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist. Persons with underlying medical conditions (other than those listed under contraindications) that might predispose to complications after wild-type influenza virus infection [e.g., chronic pulmonary, cardiovascular (except isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus)] Moderate or severe acute illness with or without fever

1. When a contraindication is present, a vaccine should NOT be administered. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization. www.cdc.gov/vaccines/hcp/acip-recs/general-recs/ contraindications.html

2. When a precaution is present, vaccination should generally be deferred but might be indicated if the benefit of protection from the vaccine outweighs the risk for an adverse reaction. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization. www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html

3. Vaccination providers should check FDA-approved prescribing information for the most complete and updated information, including contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at www.fda.gov/vaccines-blood-biologics/approved-products/vaccines-licensed-use-united-states

 \bigcirc

Appendix

Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2022

Vaccine	Contraindications ¹	Precautions ²
Dengue (DEN4CYD)	 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long- term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised) 	 Pregnancy HIV infection without evidence of severe immunosuppression Moderate or severe acute illness with or without fever
Diphtheria, tetanus, pertussis (DTaP) Tetanus, diphtheria (DT)	 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ For DTaP only: Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of previous dose of DTP or DTaP 	 Guillain-Barré syndrome (GBS) within 6 weeks after previous dose of tetanus-toxoid–containing vaccine History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid—containing or tetanus-toxoid– containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanus-toxoid– containing vaccine For DTaP only: Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, progressive encephalopathy; defer DTaP until neurologic status clarified and stabilized Moderate or severe acute illness with or without fever
Haemophilus influenzae type b (Hib)	 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ For Hiberix, ActHib, and PedvaxHIB only: History of severe allergic reaction to dry natural latex Less than age 6 weeks 	Moderate or severe acute illness with or without fever
Hepatitis A (HepA)	 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ including neomycin 	Moderate or severe acute illness with or without fever
Hepatitis B (HepB)	 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component^a including yeast For Heplisav-B only: Pregnancy 	Moderate or severe acute illness with or without fever
Hepatitis A- Hepatitis B vaccine [HepA-HepB, (Twinrix®)]	 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component^a including neomycin and yeast 	Moderate or severe acute illness with or without fever
Human papillomavirus (HPV)	 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ 	Moderate or severe acute illness with or without fever
Measles, mumps, rubella (MMR)	 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised) Pregnancy Family history of altered immunocompetence, unless verified clinically or by laboratory testing as immunocompetent 	 Recent (≤11 months) receipt of antibody-containing blood product (specific interval depends on product) History of thrombocytopenia or thrombocytopenic purpura Need for tuberculin skin testing or interferon-gamma release assay (IGRA) testing Moderate or severe acute illness with or without fever
Meningococcal ACWY (MenACWY) [MenACWY-CRM (Menveo®); MenACWY-D (Menactra®); MenACWY-TT (MenQuadfī®)]	 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ For MenACWY-D and Men ACWY-CRM only: severe allergic reaction to any diphtheria toxoid – or CRM197– containing vaccine For MenACWY-T only: severe allergic reaction to a tetanus toxoid-containing vaccine 	 For MenACWY-CRM only: Preterm birth if less than age 9 months Moderate or severe acute illness with or without fever
Meningococcal B (MenB) [MenB-4C (Bexsero®); MenB-FHbp (Trumenba®)]	 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ 	 Pregnancy For MenB-4C only: Latex sensitivity Moderate or severe acute illness with or without fever
Pneumococcal conjugate (PCV13)	 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Severe allergic reaction (e.g., anaphylaxis) to any diphtheria-toxoid– containing vaccine or its component³ 	Moderate or severe acute illness with or without fever
Pneumococcal polysaccharide (PPSV23)	 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ 	Moderate or severe acute illness with or without fever
Poliovirus vaccine, inactivated (IPV)	 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ 	Pregnancy Moderate or severe acute illness with or without fever
Rotavirus (RV) [RV1 (Rotarix®), RV5 (RotaTeq®)]	 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component^a Severe combined immunodeficiency (SCID) History of intussusception 	 Altered immunocompetence other than SCID Chronic gastrointestinal disease RV1 only: Spina bifida or bladder exstrophy Moderate or severe acute illness with or without fever
Tetanus, diphtheria, and acellular pertussis (Tdap) Tetanus, diphtheria (Td)	 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ For Tdap only: Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of previous dose of DTP, DTaP, or Tdap 	 Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of tetanus-toxoid-containing vaccine History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid- containing or tetanus-toxoid- containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanus-toxoid- containing vaccine For Tdap only: Progressive or unstable neurological disorder, uncontrolled seizures, or progressive encephalopathy until a treatment regimen has been established and the condition has stabilized Moderate or severe acute illness with or without fever
Varicella (VAR)	 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long- term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised) Pregnancy Family history of altered immunocompetence, unless verified clinically or by laboratory testing as immunocompetent 	 Recent (≤11 months) receipt of antibody-containing blood product (specific interval depends on product) Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination (avoid use of these antiviral drugs for 14 days after vaccination) Use of aspirin or aspirin-containing products Moderate or severe acute illness with or without fever

When a contraindication is present, a vaccine should NOT be administered. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization. www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html
 When a precaution is present, vaccination should generally be deferred but might be indicated if the benefit of protection from the vaccine outweighs the risk for an adverse reaction. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization. www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html
 Vaccination providers should check FDA-approved prescribing information for the most complete and updated information, including contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at www.fda.gov/vaccines-blood-biologics/approved-products/vaccines-licensed-use-united-states.

COVID-19 VACCINE RECOMMENDATIONS



COVID-19 RISK FOR SEVERE COMPLICATIONS

- Risk for Severe Complications
 - Meaning the individual may require hospitalization, intensive care, or a ventilator to help them breathe, or could die from the infection
- Older Adults
- 65 years and older
- Pregnancy
- Underlying Medical Conditions
- Long standing systemic health and social inequities

RISK FOR SEVERE COMPLICATIONS: UNDERLYING MEDICAL CONDITIONS

Cancer

Chronic Kidney Disease

Chronic lung diseases, including COPD, asthma (moderate to severe), interstitial lung disease, Cystic fibrosis, and pulmonary hypertension

Dementia or other neurological conditions

Diabetes (type 1 or type 2)

Down syndrome

Heart conditions (Heart failure, coronary artery disease, or cardiomyopathies)

HIV infection

Immunocompromised state (weakened immune system)

Liver Disease

Mental Health Conditions (mood disorders, including depression, and schizophrenia spectrum disorders)

Overweight or Obesity (body mass index (BMI) of >25 but <30kg/m2 or BMI >30 but < 40kg/m2 or > 40 kg/m2 or higher)

Pregnancy

Sickle cell disease or thalassemia

Smoking, current or former

Solid organ or blood stem cell transplant

Stroke or cerebrovascular disease

Substance use disorder

Tuberculosis

COVID-19 VACCINE OVERVIEW

mRNA vaccines

- Contain material from virus that cause COVID-19, which gives our cells instructions to make copies of the virus protein
 - Pfizer-BioNTech (received full FDA approval on August 23, 2021)
 - Brand Name Comirnaty®
 - Moderna

Vector vaccines

- Contain a modified version of a different virus than the one caused by COVID-19
- <u>Viral vector</u>
 - Janssen
- Protein Subunit vaccine
 - Novavax
 - Recombinant spike protein nanoparticle with Matrix-M1 adjuvant

COVID-19 VACCINES

mRNA vaccines

- Contain material from virus that cause COVID-19, which gives our cells instructions to make copies of the virus protein
 - Pfizer-BioNTech (received full FDA approval on August 23, 2021)
 - Moderna


Vector vaccines

- Contain a modified version of a different virus than the one caused by COVID-19
- Viral vector
 - Janssen (Johnson & Johnson)
- <u>Protein Subunit vaccine</u>
 - Novavax
 - Recombinant spike protein nanoparticle with Matrix-M1 adjuvant

ACCINE SCHEDULE (GENERAL)

COVID-19 Vaccination Schedule Infographic for People who are NOT Moderately or Severely Immunocompromised

People ages 6 months through 4 years




3-8 weeks

At least

8 weeks

People ages 6 through 11 years


4-8 weeks



At least

2 months

People ages 12 years and older



People ages 18 years and older who previously received Janssen primary series dose[‡]




*For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose. ¹ A monovalent Novavax booster dose may be used in limited situations in people ages 18 years and older who completed a primary series using any COVID-19 vaccine, have not received any previous booster dose(s), and are unable or unwilling to receive an mRNA vaccine. The monovalent Novavax booster dose is administered **at least 4 months** after completion of a primary series. ¹ Janssen COVID-19 Vaccine should only be used in certain limited situations. See: <u>https://www.cdc.gov/vaccnes/covid-19/clinical-considerations/interim-considerations-us-appendix-a</u>

VACCINE SCHEDULE (IMMUNOSUPPRESSED)

COVID-19 Vaccination Schedule Infographic for People who ARE Moderately or Severely Immunocompromised

People ages 6 months through 4 years






People ages 6 through 11 years



People ages 12 years and older



People ages 18 years and older who previously received Janssen primary series dose[‡]



Monoclonal antibodies (EVUSHELD™) for COVID-19 pre-exposure prophylaxis

People ages 12 years and older (must weigh at least 40kg)



*For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose. ¹A monovalent Novavax booster dose may be used in limited situations in people ages 18 years and obler who completed a primary series using any COVID-19 vaccine, have not received any previous booster dose(s), and are unable or unvelling to receive an mRN4 vaccine. The monovalent Novavax booster dose is administered at least 6 months after completion of a primary series.

Janssen COVID-19 Vaccine should only be used in certain limited situations. See https://www.cdc.gov/vaccines/covid-19/clinical-considerations-us-appendix.html#appendix-a

BIVALENT COVID-19 VACCINE BOOSTER DOSE RECOMMENDATIONS

Initially authorized by FDA on August 31st, 2022

mRNA vaccine

 Both protects against coronavirus original SARS-CoV-2 virus as well as B.A.4 and B.A.5 Omicron variant

Moderna and Pfizer-BioNTech

Authorized for ALL 6 months and up

Note: EUA status of monovalent vaccine was updated to no longer be used as Booster Doses (only primary 2 doses series)

DEPARTMENTS | FACULTY | TOPICS C JOHNS HOPKINS BLOOMBERG SCHOOL of PUBLIC HEALTH ACADEMICS RESEARCH PRACTICE HEADLINES ABOUT APPLY APPLY

Risk of Breakthrough COVID-19 Infection after Vaccination Is Higher Among People with HIV

Finding, based on analysis through December 31, 2021, suggests that all people with HIV might benefit from additional dose in primary vaccination



Resource:

https://publichealth.jhu.edu/2022/risk-o breakthrough.covid 19-infection-after v is-higher among-people-with-hiv

vaccination

RISK OF BREAKTHROUGH INFECTION

According to findings from a study led by researchers at the Johns Hopkins Bloomberg School of Public Health

• PLWH are at higher risk for breakthrough infection with COVID-19

Results were published June 7 in JAMA Network Open

Study found an increasing risk of breakthrough with increasing immune suppression, measured via decreasing CD4 counts

PLWH and moderate immune suppression may need to be included in the CDC's guidelines for additional doses of vaccine in the primary vaccination series

Suggesting the importance of Booster doses for this population

MONKEYPOX VACCINE ADMINISTRATION U.S. MAP



Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People™

Mpox



ħ١	Лp	ох
----	----	----

Your Health

2022 Outbreak Cases & Data

2022 U.S. Map & Case Count

2022 Global Map & Case Count

Outbreak Reproduction Number

Vaccine Administration &

U.S. Case Trends

Estimates

Effectiveness

2022 Outbreak C	ases and Data
-----------------	---------------

Data as of March 15 2023 at 2:00 pm EDT

Español | Print

Beginning February 1, 2023, the data below will be updated every two weeks.

U.S. Cases	U.S. Deaths	Global Cases
Total Cases	Total Deaths	Total Cases
30,262	38	86,500



At this time, data suggest that gay, bisexual, and other men who have sex with men make up the majority of cases in the current mpox outbreak. However, anyone, regardless of sexual orientation or gender identity, who has been in close, personal contact with someone who has mpox is at risk. Take steps to prevent getting mpox. If you have any symptoms of mpox, talk to a healthcare provider.

TPOXX Patient Data

Laboratory Testing

Case Demographics

Vaccination

ACAM2000

- Live vaccinia virus vaccine
- Licensed by FDA in August 2007

Jynneos®


40

- Live Vaccinia virus but is NOT replication competent
- Dosed as 2 injections 28 days apart
- Administration
 - 18 years and up
 - Intradermal
 - Under 18 years
 - Subcutaneous
- Currently only available for at risk and post-exposure prophylaxis (household contacts, known exposures, or likely exposure) with in 4 days of exposure



- Intradermal Technique
 - https://youtube.com/shorts/DIENkC5Zwg4?feature=share
- Intradermal administration
 - Two doses of 0.1 mL
- Individuals <18 years of age
 - Dosed as two 0.5 mL
- Leave bleb uncovered if administered intradermally
- Do NOT massage, rub, or scratch the bleb


Note: Those receiving intradermal injection have complained of being "scared" or having discoloration at the site of injection





MONKEY**POX**

How to administer a JYNNEOS vaccine intradermally



M O N K E Y **P O X**

How to administer a JYNNEOS vaccine intradermally



Slowly inject 0.1mL This should produce a noticeable pale elevation

Intradermal Administration

BEST PRACTICES

GET TO KNOW THE COMMUNITY

Éducate yourself about the community!!

June is PRIDE month

You should know the history and why its important to commemorate in the community

Know the correct and culturally appropriate terminology

- LGBTQIA+ Glossary of Terms for Health Care Teams (Fenway Institute)
 - <u>https://www.lgbtqiahealtheducation.org/wp-</u> content/uploads/2020/02/Glossary-2022.02.22-1.pdf

Stay up to date on the latest information

Use pronouns

- State yours
- Provide trauma informed care



We Are The National LGBTQIA+ Health Education Center

We provide educational programs, resources, and consultation to health care organizations with the goal of optimizing quality, cost-effective health care for lesbian, gay, bisexual, transgender, queer, intersex, asexual, and all sexual and gender minority (LGBTQIA+) people.

Ready to Learn?

Access our extensive library of webinars, publications, and more, and earn CME credit on eligible materials.

Want to Connect?

Interested in a speaker or training at your organization? Looking for additional resources? Get in touch with us today! Get Started

What's New?

Housing and Older LGBTQIA+ Adults – Part 2

🕨 Webinar


23 March, 2021

For this webinar series, The National LGBTQIA+ Health Education Center is partnering with National Center for Equitable Care for Elders, The Corporation for Supportive Housing, The National Health Care for the Homeless Council and the National Center for Health in Public Housing to highlight the importance of housing security for Older LGBTQIA+ Adults.

Read More »

The Fenway Institute - National LGBT Health Education Center https://www.lgbthealtheducation.org/

Educational Resource



IMMUNIZATION ACTION COALITION

http://www.immunize.org/

BEST PRACTICES

Effective communication involves the whole healthcare team

- Know the appropriate terminology
- It only takes one person in the office/practice to make the patient feel "uncomfortable" and have them walk out the door

Avoid assumptions

 Don't assume to know the persons gender identity or sexual orientation based on how they appear

Don't assume that you know how a persons or their partners want to be described

Don't assume that ALL patients are heterosexual and cisgender (not transgender)



- To prevent making mistakes about gender identity or sexual orientation with new patients, use gender-neutral terms and avoid using gender specific pronouns
- Be sure to use the patients preferred name and pronouns
- Transgender person often change their name to affirm their gender identity
 - Can be different than what is listed on their insurance or identity documents

BEST PRACTICES

Forms used by your medical facility should have a space for the patients preferred name and pronouns

- Should be included in all medical records
- Actively collect "SOGI" data
- Used by all staff members consistently

Creating an environment of accountability and respect requires everyone to work together

Don't be afraid to politely correct your colleagues if they make a mistake or make insensitive comments

Making the patient feel as comfortable as possible will help you to provide them with the best care

BEST PRACTICES FOR VACCINES

Incorporate vaccine assessment into your care

- Conduct this at each health visit
- Can be done by nurse/MA during intake processing

 Utilize your states vaccination registry to screen and identify when vaccinations are missing

Examples

Nevada - WeblZ



ADDING LGBTQ+ TO SEXUAL HISTORY TAKING

- Take a sexual history
 - Should be incorporated into all health visits and part of routine care
 - Will help to identify possible indications for vaccinations
- The 5 "P" + 3 more
 - Partners
 - Practices
 - Past (history of STIs)
 - Protection
 - Pregnancy

New "P"s

- Pleasure
- Problems

51

BEST PRACTICES FOR VACCINES

- Provide vaccinations on site
- Vaccinations will be readily available if the vaccine assessment shows that they are indicated to receive immunizations
- Setting this up in your practice will ensure that patients are up to date with their vaccinations and as protected as possible
 - Utilizing state immunization registries can help you with this process
 - Register with the state to be a vaccine provider
- You can register receive 317 vaccines from the state for those who are uninsured or underinsured
- Saves time and can be profitable depending on the vaccination
 - Charge for administration fee
 - Billed to insurance as a covered preventative health benefit at no cost to the patient

- https://www.cdc.gov/lgbthealth/
- https://www.lgbthealtheducation.org/
- https://www.cdc.gov/vaccines/schedules/hcp/
- https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
- https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-5yrs-older.pdf
- https://publichealth.jhu.edu/2022/risk-of-breakthrough-covid-19-infection-after-vaccination-is-higher-among-people-with-hiv

References



Question & Answer Period with

Christina M. Madison, Pharm.D., FCCP, AAHIVP

Have a Question?	Locate the Q & A box and type them there. We will address as many questions as we can today.	
Complete Survey for CEU Credit	In order to receive CEU credit for attending today's webinar, please complete the survey at the end of today's program.	